Electronic Supplementary Material (ESI) for Journal of Materials Chemistry B. This journal is © The Royal Society of Chemistry 2024

Supporting Information

One-step immunoassay based on switching peptides for diagnosis of porcine epidemic diarrhea virus (PEDV) using screened F_v-antibodies

Tae-Hun Kim,^a Jae-Yeon Park,^b Jaeyong Jung,^a Jeong Soo Sung,^a Soonil Kwon,^a Hyung Eun Bae, ^a Hyun-Jin Shin,^b Min-Jung Kang,^c Joachim Jose,^d and Jae-Chul Pyun^{*a}

^aDepartment of Materials Science and Engineering, Yonsei University, 50 Yonsei-Ro, Seodaemun-Gu, Seoul 03722, Korea

^bCollege of Veterinary Medicine, Chungnam National University, Daejeon, 34134, South Korea

^cKorea Institute of Science and Technology (KIST), Seoul, Korea

^dInstitute of Pharmaceutical and Medical Chemistry, Westfälischen Wilhelms-Universität Münster, Muenster, Germany.

*To whom correspondence should be addressed

*Corresponding author: Jae-Chul Pyun, Tel.: +82 2 2293 5509; Fax: 82 2 312 5375; Email: jcpyun@yonsei.ac.kr



Fig. S1 Expression of RBD antigen from PEDV (strain CV777) S protein for the screening of Fvantibody library. The RBD consisted of 129 amino acid residues (21.2 kDa), which included a part of the S protein (amino acid number from 582 to 781). SDS-PAGE showed the GFP (26.9 kDa) and His-tag were included in the structure of RBD antigen (49 kDa).



Fig. S2 An autodisplayed F_V -library with a randomized CDR3 region was used to screen for F_V antibodies against PEDV S protein. (A) Preparation of the F_V -library with a randomized CDR3 region in the V_H using site-directed mutagenesis. (B) Expression of the F_V -library on the outer membrane of *E. coli* using an autodisplay vector (SDS-PAGE of the autodisplayed F_V -variant, control strain with CDR1 and CDR2, and intact *E. coli*).



Fig. S3 Specificity test of Fv-antibodies (Anti-RBD-1, Anti-RBD-2, Anti-RBD-3, and Anti-RBD-4) using the positive sample (PEDV) and negative control samples (HCoV-229E, SARS-CoV-1, and SARS-CoV-2) to Fv-antibodies.



Fig. S4 Quantitative analysis of the RNA from PEDV in supernatant media of Vero cell was extracted using Patho Gene-spin[™] DNA/RNA extraction kit from iNtRON Biotechnology (Gyeonggi-do, Korea). The amount of RNA from each diluted PEDV samples were analyzed using PEDV PCR reaction kit from iNtRON Biotechnology (Gyeonggi-do, Korea). The PCR reaction was performed according to the manufacturer's instructions. After PCR reaction. the band intensity was calculated using software (ImageJ).



Fig. S5 Analysis of interaction between screened F_V-antibodies (Anti-RBD-1, Anti-RBD-2, Anti-RBD-3, Anti-RBD-4) and RBD antigen from PEDV S protein (Uniprot ID: Q91AV1) using molecular docking software.

Table S1. Primer sequences of randomized CDR3 region of the F_V-antibody library. Randomized forward primer (75 bases) and corresponding reverse primer (22 bases) and composition of nucleotides at each position were listed in the table.

| Primer type | Oligonucleotide sequence | |
|------------------------------|--|--|
| Randomized forward primer | 5'-GTCTATTATTGCGCTCGT ¹ KRYVNN ⁷ VNNVNN ¹³ VNNVNN ¹⁹ VNNVNN ²⁵ VNNGAT | |
| (75 bases) | ³¹ KWYTGGGGTCAAGGTACTACGGTTACG-3' | |
| Corresponding reverse primer | 3'-CCCAGTTCCATGATGCCAATGC-5' | |
| (22 bases) | | |
| Composition of nucleotides | N = A, C, G, T / R = A, G / K = G, T / Y = C, T / W = A, T / V = A, C, G | |
| at each position | | |

Table S2. Amino acid and corresponding oligonucleotide sequences of F_{v} -antibody. The CDR3 sequence was randomized for the preparation of F_{v} -antibody library from the template using site-directed mutagenesis.

| Region | Amino acid (N \rightarrow C-term) | Oligonucleotide sequence (5' \rightarrow 3') | |
|------------|-------------------------------------|---|--|
| Frame-1 | EVQLVESAAEVRRPGASVKITCKASGYSFS | GAA GTG CAG CTC GTG GAA AGC GCT GCC GAA GTT CGG CGT CCT GGG GCT AGC GTG AAG ATC ACC TGC AAA GCG TCC GGC TAT TCA TTC AGC | |
| CDR1 | TYGIQ | ACC TAT GGG ATT CAG | |
| Frame-2 | WMRQAPGQRPEWLG | TGG ATG CGC CAA GCG CCA GGC CAG CGT CCG GAA TGG CTT GGG | |
| CDR2 | WIHAGTGGTKYSRKFQG | TGG ATA CAT GCA GGC ACA GGT GGG ACT AAG TAC TCG CGC AAA TTT CAG GGT | |
| Frame-3 | RITITRDTSANTVYLDLNSLTSEDTAVYYCAR | CGC ATT ACT ATC ACC CGT GAT ACC AGC GCG AAT ACC GTC TAT CTG GAT CTG | |
| | | AAC TCT CTG ACA TCG GAG GAT ACG GCC GTC TAT TAT TGC GCT CGT | |
| CDR3 | DKVTVWACQDN | GAC AAA GTT ACA GTC TGG GCT TGT CAG GAT AAT | |
| (Template) | | | |
| Frame-4 | WGQGTTVTVSS | TGG GGT CAA GGT ACT ACG GTT ACG GTC AGC AGT | |

Table S3. Analytic parameters of L1-switching peptide. The peptide was synthesized from Peptron Co. (Daejeon, Korea) using solid-phase Fmoc chemistry under consecutive flow conditions. The synthesized peptides were purified using reverse-phase HPLC (High-Performance Liquid Chromatography) and lyophilized.

| Switching peptide | Amino acid sequence | Molecular weight (g/mol) | Purity |
|-------------------|--|--------------------------|--------|
| L1-peptide | TYLEW ⁵ YPQKP ¹⁰ GQSPK ¹⁵ LLIYK ²⁰ | 2,452 | 90 % |